CBN (Cannabinol).
May provide mild sedation and relaxation. Marketed as a natural sedative for sleep. It's a minor cannabinoid that forms when THC breaks down. The idea is it makes you relaxed and sleepy.
Reviewed March 2026
- Category
- Active compound
- Also filed under
- May promote relaxationCould improve sleep quality
What CBN (Cannabinol) is, and what it does.
- Does it work
- Suits people who want a mild evening cannabinoid and who read the certificate of analysis. If you want a well mapped sleep ingredient, magnesium and melatonin carry more human data.
- How much to take
- Start low, around 2-5mg before bed. Most products are in this range. Higher doses don't have more data to back them up.
- Time to feel it
- Taken in the evening, anything you notice lands within one to two hours as it clears the liver. It's a same-night ingredient rather than one that builds.
- The first dose
- Maybe a slight feeling of calm an hour or two after. Or nothing. It's very subtle and inconsistent.
- With regular use
- No real long-term data. It's not something that builds up. You take it for an effect that night.
- How well tolerated
- Seems well tolerated at low doses. The main risk is drowsiness and potential interactions with other sedatives. Lack of regulation is a bigger concern.
- How it feels
- A mild, sometimes barely-there sense of relaxation. Not a powerful sedative like a sleeping pill. Very hit-or-miss.
- The overlooked benefit
- Its level in a hemp extract is a storage record. Cannabinol builds up as plant material ages, so the batch assay tells you how that material was handled.
3 to 5mg a day is where CBN (Cannabinol) works.
Source: Sleep medicine supplement industry data. Very limited clinical evidence.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
While CBN has shown some potential in preliminary studies, more robust research is needed to confirm its benefits, especially at supplement-relevant doses. Many studies are preclinical or use isolated cells. Human trials are needed.
- Sleep qualityRandomised trial
- Evening relaxation and sedationNarrative review
- Partial cannabinoid receptor agonismIn vitro study
Questions people ask about CBN (Cannabinol).
- Will CBN get me high?
- No. It's not intoxicating like THC. You might feel sleepy, but not high.
- Is it legal?
- It's complicated. Generally legal if derived from hemp with less than 0.3% THC, but state laws vary. Check your local regulations.
- Is it better than melatonin?
- Different, and way less studied. Melatonin has decades of research for sleep timing. CBN has almost none in humans.
- Can I take it with CBD?
- Yes, they're often sold together. Some believe they work better in combination, but that's still theory.
- Does it work for pain?
- Very little evidence for that. The main claim is sedation, not pain relief.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Cannabinol is a highly lipophilic, essentially water-insoluble molecule, so it is dissolved into a carrier oil for any liquid format. Medium-chain triglycerides are a usual choice because they stay liquid, resist oxidation and carry cannabinoids into the lymphatic route with dietary fat. This is delivery chemistry, not an added pharmacological effect.
Lecithin phospholipids reduce interfacial tension, which is how an oil-phase cannabinoid is dispersed into a water-based drink or a soft chew without separating. Formulators use it to hold an emulsion, and it is also the basis of liposomal and nanoemulsion presentations. The row describes a formulation function rather than a benefit.
Cannabinol itself is an oxidation product, and the oil it sits in is also oxidisable. Tocopherols are added to lipid fills as chain-breaking antioxidants to slow peroxide formation over shelf life. The function is stability, and it says nothing about what either does in the body.
Rosemary extract standardised to carnosic acid is a common natural antioxidant in oils and is used where a label prefers a plant-derived stabiliser. In a cannabinoid oil its job is protecting the carrier. Early confidence and purely a formulation role.
Piperine inhibits several CYP isoforms and glucuronidation, which is why it appears next to poorly bioavailable actives. Cannabinoids are cleared through those same routes, so the pairing can raise exposure in an unpredictable way rather than simply improving absorption. That makes it a flag for anyone on medication cleared by the same enzymes, not a selling point.
Melatonin signals darkness at MT1 and MT2 receptors while cannabinol acts on cannabinoid receptors, so the two reach an evening effect by separate routes and are commonly sold together. The practical note is that sedative-direction effects can add. No combination trial supports this pairing in the candidate set.
Theanine is a glutamate analogue associated with alpha-wave activity and a relaxed but alert state, which is a different mechanism from cannabinoid receptor binding. They are combined in evening and unwind formulas. Early confidence, additive direction, mechanism-level only.
Magnesium modulates NMDA receptor activity and glycine is itself an inhibitory neurotransmitter, so this salt is used in evening formulas alongside cannabinoids. The two act at different sites and their calming directions may add. Early confidence, no combination study.
Valerian preparations show GABA-system activity in vitro and have a long history in evening use. Combined with cannabinol the sedative direction is shared, which is worth stating for anyone also taking a prescribed sedative. Mechanism-level pairing only.
Chamomile is standardised to apigenin, a flavone with benzodiazepine-site binding described in laboratory studies. It appears with cannabinol in night formulas. Early confidence, additive direction.
Passionflower is used in evening blends and its effects point the same way as a cannabinoid taken at night. The two have no established mechanistic link. Listed as an additive-direction flag at early confidence.
Lemon balm constituents have been described as inhibiting GABA transaminase in laboratory work, which is a different route to the same evening direction as cannabinoid receptor binding. The combination is common in night products. In vitro mechanism, early confidence.
Honokiol and magnolol have GABA-A activity described in laboratory studies, and magnolia bark is a staple of evening stacks. Paired with cannabinol the sedative direction may add. Early confidence and a monitoring note rather than a benefit claim.
Glycine is an inhibitory neurotransmitter at its own receptor and a co-agonist at NMDA receptors, and it is used in evening formulas at gram-level doses. Its route is separate from cannabinoid receptor binding, so the directions may add without interacting. Early confidence.
Caffeine blocks adenosine receptors and lengthens the time to sleep onset, which opposes what an evening cannabinol product is taken for. In a same-day stack the timing gap is the whole point. This is an anti-synergy worth stating plainly.
Talk to a doctor before taking CBN (Cannabinol) if any of these apply to you: May cause drowsiness, Potential interactions with other sedatives, Avoid operating heavy machinery, Pregnancy/Breastfeeding. These are flags to check first, not effects CBN (Cannabinol) is known to cause.
Not medical advice. Show the label to your pharmacist.What CBN (Cannabinol) actually does.
CBN is what THC turns into as it ages or gets heated and lit.
It only dissolves in fat, so the oil it comes in and whether you eat with it both matter.
More CBN in an extract usually means older or roughly handled material, not a special plant.
The plant's chemistry shifts with variety and growing conditions, so each batch has to be tested.
Where CBN (Cannabinol) comes from.
CBN is generally made, not picked. It comes from turning another cannabinoid into it, or from building it in a lab, and the certificate of analysis is what tells you what is actually in the batch.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
Cannabinol occurs in the plant only in small amounts, and mostly in aged material, so production usually starts from another cannabinoid rather than from fresh flower.
Controlled exposure to heat, light, oxygen or a catalyst converts tetrahydrocannabinol to cannabinol; alternatively the molecule is built synthetically from non-cannabis starting materials.
The target cannabinoid is separated from reaction by-products and residual cannabinoids, then crystallised for an isolate or held as a distillate.
Batches are assayed by chromatography for cannabinol content, residual tetrahydrocannabinol, residual solvents and heavy metals.
The purified material is dissolved into a carrier oil, emulsified for water-based products, or carried on a powder excipient.
Labels seldom say whether the cannabinol came from natural ageing, a deliberate conversion step or full synthesis, and residual tetrahydrocannabinol content lives on the certificate of analysis rather than the panel.
The forms it comes in.
The essence, in one line each.
- A cannabinoid blend containing cannabinol was tested in adults reporting mild trouble sleeping and self-reported sleep quality and mood scores improved over the trial period, so the effect cannot be attributed to cannabinol alone.Randomised trial. Hausenblas et al., 2025 (Health science reports). PMID 39980821 ↗
- A systematic review of inflammatory biomarker changes with cannabidiol and tetrahydrocannabinol; these are markers rather than outcomes, and the review is about those two cannabinoids rather than cannabinol.Systematic review. Candeloro BM et al., 2025 (International Journal of Molecular Sciences). PMID 41373770 ↗
- An overview of phytocannabinoid mechanism of action, production and the factors that affect content; it names cannabinol within that broader survey and grounds mechanism rather than any effect.Narrative review. Jurga M et al., 2024 (International Journal of Molecular Sciences). PMID 39457041 ↗
- Cannabinoid and terpenoid content of the plant varied with growing conditions, which supports the point that raw material composition is an agronomic variable.In vitro study. Chacon FT et al., 2025 (Journal of Medicinally Active Plants). PMID 41323359 ↗
- Cannabis plant residue was assessed in a ruminant fermentation model; the work concerns feed and rumen microbiology and carries no information about cannabinol taken by people.Animal study. Hnokaew P et al., 2025 (BMC Veterinary Research). PMID 41088333 ↗
These are the studies our verdict leans on, chosen from the 93 we read for CBN (Cannabinol). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.